Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 4/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | PTGIR | P43119 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15295154 | 1.00 | ACLY (0.42) | ACLYPTGDR2EPHA2KDREPHB4 | |
| SCHEMBL15287460 | 0.92 | ACLY (0.45) | ACLYPTGDR2EPHA2KDREPHB4 | |
| SCHEMBL15295158 | 0.92 | ACLY (0.42) | ACLYPTGDR2EPHA2KDREPHB4 | |
| SCHEMBL16675394 | 0.92 | ACLY (0.42) | ACLYPTGDR2EPHA2KDREPHB4 | |
| SCHEMBL15295335 | 0.91 | ACLY (0.42) | ACLYPTGDR2EPHA2KDREPHB4 | |
| SCHEMBL4014930 | 0.90 | ACLY (0.51) | ACLYPTGDR2EPHA2KDREPHB4 | |
| SCHEMBL4318896 | 0.90 | ACLY (0.51) | ACLYPTGDR2EPHA2KDREPHB4 | |
| SCHEMBL15295148 | 0.89 | ACLY (0.45) | ACLYPTGDR2EPHA2KDREPHB4 | |
| SCHEMBL16675380 | 0.89 | ACLY (0.45) | ACLYPTGDR2EPHA2KDREPHB4 | |
| SCHEMBL15295224 | 0.89 | ACLY (0.46) | ACLYPTGDR2EPHA2KDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119394-A1 | Insulin-Like Growth Factor-1 Receptor Inhibitors | MERCK SHARP & DOHME CORP. | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119394-A1 | Insulin-Like Growth Factor-1 Receptor Inhibitors | IGF1R, IGFBP1, INSR | ACLY 1860/4885PTGDR2 1387/4885EPHA2 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.